Differentiating Scleroderma from other diseases: Difference between revisions
No edit summary |
No edit summary |
||
Line 172: | Line 172: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |Skin changes present on trunk sparing extremities | | style="background: #F5F5F5; padding: 5px;" | | ||
* Skin changes present on trunk sparing extremities | |||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Chronic graft-versus-host disease | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Chronic graft-versus-host disease | ||
Line 190: | Line 191: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |Occurs after allogeneic hematopoietic transplantation | | style="background: #F5F5F5; padding: 5px;" | | ||
* Occurs after allogeneic hematopoietic transplantation | |||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Drug induced scleroderma | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Drug induced scleroderma | ||
Line 265: | Line 267: | ||
* Perivascular infiltrate in the dermis | * Perivascular infiltrate in the dermis | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |Symmetric proximal muscle weakness | | style="background: #F5F5F5; padding: 5px;" | | ||
* Symmetric proximal muscle weakness | |||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Rheumatoid arthritis | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Rheumatoid arthritis | ||
Line 292: | Line 295: | ||
* Inflammation at the dermal-epidermal junction | * Inflammation at the dermal-epidermal junction | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |Clinical findings that suggest rheumatoid arthritis (RA) but do not fulfill the ACR criteria for RA | | style="background: #F5F5F5; padding: 5px;" | | ||
* Clinical findings that suggest rheumatoid arthritis (RA) but do not fulfill the ACR criteria for RA | |||
|- | |- | ||
| rowspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" |Endocrine disorders | | rowspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" |Endocrine disorders | ||
Line 310: | Line 314: | ||
| style="background: #F5F5F5; padding: 5px;" | - | | style="background: #F5F5F5; padding: 5px;" | - | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |Long standing type I diabetes | | style="background: #F5F5F5; padding: 5px;" | | ||
* Long standing type I diabetes | |||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Myxedema due to hypothyroidism<ref name="pmid1607406">{{cite journal |vauthors=Heymann WR |title=Cutaneous manifestations of thyroid disease |journal=J. Am. Acad. Dermatol. |volume=26 |issue=6 |pages=885–902 |date=June 1992 |pmid=1607406 |doi= |url=}}</ref> | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Myxedema due to hypothyroidism<ref name="pmid1607406">{{cite journal |vauthors=Heymann WR |title=Cutaneous manifestations of thyroid disease |journal=J. Am. Acad. Dermatol. |volume=26 |issue=6 |pages=885–902 |date=June 1992 |pmid=1607406 |doi= |url=}}</ref> | ||
Line 333: | Line 338: | ||
* Hyperkeratosis | * Hyperkeratosis | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |Hypothyroidism | | style="background: #F5F5F5; padding: 5px;" | | ||
* Hypothyroidism | |||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Renal diseases | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Renal diseases |
Revision as of 13:57, 20 April 2018
Scleroderma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Differentiating Scleroderma from other diseases On the Web |
American Roentgen Ray Society Images of Differentiating Scleroderma from other diseases |
Risk calculators and risk factors for Differentiating Scleroderma from other diseases |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: M. Khurram Afzal, MD [2]
Overview
[Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as [differential dx1], [differential dx2], and [differential dx3].
OR
[Disease name] must be differentiated from [[differential dx1], [differential dx2], and [differential dx3].
Differentiating X from other Diseases
- [Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as [differential dx1], [differential dx2], and [differential dx3].
- [Disease name] must be differentiated from [differential dx1], [differential dx2], and [differential dx3].
- As [disease name] manifests in a variety of clinical forms, differentiation must be established in accordance with the particular subtype. [Subtype name 1] must be differentiated from other diseases that cause [clinical feature 1], such as [differential dx1] and [differential dx2]. In contrast, [subtype name 2] must be differentiated from other diseases that cause [clinical feature 2], such as [differential dx3] and [differential dx4].
Preferred Table
Diseases | Clinical manifestations | Para-clinical findings | Gold standard | Additional findings | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Symptoms | Physical examination | |||||||||||||
Lab Findings | Imaging | Histopathology | ||||||||||||
Skin thickening | Raynaud phenomenon | Heart burn | Edema (swelling) | Sclerodactyly | Telangiectasia | Impaired mobility | Autoantibodies | Blood indices | ||||||
Scleroderma[1][2] | Limited cutaneous systemic sclerosis (CREST syndrome) | +
(induration) |
+ | + | +/- | + | + | +/- |
|
|
|
|
| |
Diffuse cutaneous systemic sclerosis | +
(induration) |
+ | + | +/- | + | + | +/- |
|
|
|
|
| ||
Systemic diseases | Scleredema
(Buschke's disease)[3] |
+ | - | - | + | - | - | + | - | - | - |
|
| |
Scleromyxedema
(lichen myxedematosus) |
|
|||||||||||||
Amyloidosis | ||||||||||||||
Eosinophilic fasciitis | + |
|
| |||||||||||
Chronic graft-versus-host disease | +
(induration) |
- |
|
| ||||||||||
Drug induced scleroderma | ||||||||||||||
Scleroderma overlap syndromes[4][5][6][7] | Systemic lupus erythematosus | +
(rash) |
+ | + | +/- | + | + | +/- |
|
|
|
| ||
Polymyositis | +
(rash) |
+ | + | +/- | + | + | +/- |
|
|
|
| |||
Rheumatoid arthritis | +
(rash) |
+ | + | +/- | + | + | +/- |
|
|
|
| |||
Endocrine disorders | Diabetes mellitus (diabetic cheiroarthropathy)[8][9] | +
(waxy skin) |
- | - | - | + | - | + | - | - |
| |||
Myxedema due to hypothyroidism[10] | +
(coarse skin) |
- | - | + | - | - | - |
|
|
|
| |||
Renal diseases | Nephrogenic systemic fibrosis[11] | +
(induration) |
- | - | + | + | - | - | - |
|
|
|
References
- ↑ LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, Rowell N, Wollheim F (February 1988). "Scleroderma (systemic sclerosis): classification, subsets and pathogenesis". J. Rheumatol. 15 (2): 202–5. PMID 3361530.
- ↑ Black CM (August 1993). "Scleroderma--clinical aspects". J. Intern. Med. 234 (2): 115–8. PMID 8340733.
- ↑ Rongioletti F, Kaiser F, Cinotti E, Metze D, Battistella M, Calzavara-Pinton PG, Damevska K, Girolomoni G, André J, Perrot JL, Kempf W, Cavelier-Balloy B (December 2015). "Scleredema. A multicentre study of characteristics, comorbidities, course and therapy in 44 patients". J Eur Acad Dermatol Venereol. 29 (12): 2399–404. doi:10.1111/jdv.13272. PMID 26304054.
- ↑ Satoh M, Chan EK, Sobel ES, Kimpel DL, Yamasaki Y, Narain S, Mansoor R, Reeves WH (September 2007). "Clinical implication of autoantibodies in patients with systemic rheumatic diseases". Expert Rev Clin Immunol. 3 (5): 721–38. doi:10.1586/1744666X.3.5.721. PMID 20477023.
- ↑ Moinzadeh P, Aberer E, Ahmadi-Simab K, Blank N, Distler JH, Fierlbeck G, Genth E, Guenther C, Hein R, Henes J, Herich L, Herrgott I, Koetter I, Kreuter A, Krieg T, Kuhr K, Lorenz HM, Meier F, Melchers I, Mensing H, Mueller-Ladner U, Pfeiffer C, Riemekasten G, Sárdy M, Schmalzing M, Sunderkoetter C, Susok L, Tarner IH, Vaith P, Worm M, Wozel G, Zeidler G, Hunzelmann N (April 2015). "Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis". Ann. Rheum. Dis. 74 (4): 730–7. doi:10.1136/annrheumdis-2013-204487. PMC 4392314. PMID 24389298.
- ↑ Foocharoen C, Netwijitpan S, Mahakkanukrauh A, Suwannaroj S, Nanagara R (September 2016). "Clinical characteristics of scleroderma overlap syndromes: comparisons with pure scleroderma". Int J Rheum Dis. 19 (9): 913–23. doi:10.1111/1756-185X.12884. PMID 27126733.
- ↑ Pakozdi A, Nihtyanova S, Moinzadeh P, Ong VH, Black CM, Denton CP (November 2011). "Clinical and serological hallmarks of systemic sclerosis overlap syndromes". J. Rheumatol. 38 (11): 2406–9. doi:10.3899/jrheum.101248. PMID 21844148.
- ↑ Seibold JR (November 1982). "Digital sclerosis in children with insulin-dependent diabetes mellitus". Arthritis Rheum. 25 (11): 1357–61. PMID 6753855.
- ↑ Jelinek JE (April 1993). "The skin in diabetes". Diabet. Med. 10 (3): 201–13. PMID 8485952.
- ↑ Heymann WR (June 1992). "Cutaneous manifestations of thyroid disease". J. Am. Acad. Dermatol. 26 (6): 885–902. PMID 1607406.
- ↑ Galan A, Cowper SE, Bucala R (November 2006). "Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy)". Curr Opin Rheumatol. 18 (6): 614–7. doi:10.1097/01.bor.0000245725.94887.8d. PMID 17053507.